BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36071824)

  • 1. Risk Factors and Predictive Model for Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease.
    Wang K; Tian Y; Liu S; Zhang Z; Shen L; Meng D; Li J
    Pharmgenomics Pers Med; 2022; 15():775-783. PubMed ID: 36071824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of rapidly progressive interstitial lung disease and prognosis in Chinese patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis.
    Li M; Zhao X; Liu B; Zhao Y; Li X; Ma Z; Yang Q
    Front Immunol; 2023; 14():1209282. PubMed ID: 37691917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
    Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
    Front Immunol; 2022; 13():845988. PubMed ID: 35320936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nomogram based on clinical factors and CT radiomics for predicting anti-MDA5+ DM complicated by RP-ILD.
    Li Y; Deng W; Zhou Y; Luo Y; Wu Y; Wen J; Cheng L; Liang X; Wu T; Wang F; Huang Z; Tan C; Liu Y
    Rheumatology (Oxford); 2024 Mar; 63(3):809-816. PubMed ID: 37267146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction model for the pretreatment evaluation of mortality risk in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease.
    Gui X; Li W; Yu Y; Zhao T; Jin Z; Meng K; Wang R; Shi S; Yu M; Ma M; Chen L; Luan W; Xin X; Qiu Y; Qiu X; Zhang Y; Cao M; Cao M; Dai J; Cai H; Huang M; Xiao Y
    Front Immunol; 2022; 13():978708. PubMed ID: 36211445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Clinical Risk Model to Predict Rapidly Progressive Interstitial Lung Disease Incidence in Dermatomyositis.
    Li Y; Li Y; Wang Y; Shi L; Lin F; Zhang Z; Zhang J; Liu Y; Liu X; Xu F; Sun X
    Front Med (Lausanne); 2021; 8():733599. PubMed ID: 34646845
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: The CRAFT Model.
    Guo J; Mei C; Yu Q; Huang A
    Med Sci Monit; 2023 Jun; 29():e940251. PubMed ID: 37317506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury].
    Zhang PL; Yang HX; Zhang LN; Ge YP; Peng QL; Wang GC; Lu X
    Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 53(6):1055-1060. PubMed ID: 34916681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
    Li Y; Li Y; Wu J; Miao M; Gao X; Cai W; Shao M; Zhang X; Xu Y; Cong L; He J; Sun X
    J Immunol Res; 2020; 2020():2024869. PubMed ID: 33299896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of dermatomyositis patients with isolated anti-Ro-52 antibody associated rapid progressive interstitial lung disease: Data from the largest single Chinese center.
    Chen F; Zuo Y; Li S; Shi J; Wang G; Shu X
    Respir Med; 2019 Aug; 155():127-132. PubMed ID: 31344662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
    Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
    Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progranulin correlated with rapid progressive interstitial lung disease in dermatomyositis with anti-melanoma differentiation-associated gene 5 antibody.
    Shanshan L; Yamei Z; Ling Z; Xin L; Guochun W
    Clin Rheumatol; 2022 Mar; 41(3):757-763. PubMed ID: 34718893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy.
    Ge Y; Li S; Tian X; He L; Lu X; Wang G
    Clin Rheumatol; 2021 Jun; 40(6):2311-2317. PubMed ID: 33411136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis.
    Wang Q; Gao C; Zhang C; Yao M; Liang W; Sun W; Zheng Z
    Clin Rheumatol; 2022 Jun; 41(6):1731-1739. PubMed ID: 35138465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease.
    Zhu Y; Wang L; Sun Y; Wang J; Lv C; You H; Xu L; Wang F; Zhang M; Tan W; Ke Y
    Clin Exp Rheumatol; 2022 Feb; 40(2):292-297. PubMed ID: 34874831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
    Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
    Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
    Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
    Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
    Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
    Front Immunol; 2022; 13():879266. PubMed ID: 35603153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
    Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.